Evidence map›Paper›PMID 35141971›Full record

Trial reportHuman brain mapping2022

Immediate and long-term effects of speech treatment targets and intensive dosage on Parkinson's disease dysphonia and the speech motor network: Randomized controlled trial.

Shalini Narayana, Crystal Franklin, Elizabeth Peterson, Eric J Hunter, Donald A Robin, Angela Halpern, Jennifer Spielman, Peter T Fox, Lorraine O Ramig

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Human brain mapping, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Sensorimotor Adaptation to a Nonuniform Formant Perturbation Is Preserved in Healthy Aging.Journal of speech, language, and hearing research : JSLHR · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Shalini NarayanaDepartment of Pediatrics, Division of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA.ORCID 0000-0002-0116-5785
Crystal FranklinResearch Imaging Institute, University of Texas Health Science Center, San Antonio, Texas, USA.ORCID 0000-0002-7382-1315
Elizabeth PetersonLSVT Global Inc, Tucson, Arizona, USA.
Eric J HunterDepartment of Communicative Sciences and Disorders, Michigan State University, Lansing, Michigan, USA.ORCID 0000-0001-5571-464X
Donald A RobinDepartment of Communication Sciences and Disorders, University of New Hampshire, Durham, New Hampshire, USA.
Angela HalpernLSVT Global Inc, Tucson, Arizona, USA.
Jennifer SpielmanNational Center for Voice and Speech and Department of Speech-Language and Hearing Sciences, University of Colorado-Boulder, Boulder, Colorado, USA.
Peter T FoxResearch Imaging Institute, University of Texas Health Science Center, San Antonio, Texas, USA.ORCID 0000-0002-0465-2028
Lorraine O RamigLSVT Global Inc, Tucson, Arizona, USA.
NSF National Center for Atmospheric Research · USThe University of Texas Health Science Center at San Antonio · USLSVT Global (United States) · USMichigan State University · USUniversity of New Hampshire · USUniversity of Tennessee Health Science Center · US

Funding

EFFICACY OF VOICE TREATMENT FOR PARKINSONS DISEASER01DC001150 · NIDCD · UNIVERSITY OF COLORADO AT BOULDER · PI RAMIG, LORRAINE O. · 1990 to 2011
$5.8M
NIDCD NIH HHS R01 DC001150
6 · The paper itself

Abstract

This study compared acoustic and neural changes accompanying two treatments matched for intensive dosage but having two different treatment targets (voice or articulation) to dissociate the effects of treatment target and intensive dosage in speech therapies. Nineteen participants with Parkinsonian dysphonia (11 F) were randomized to three groups: intensive treatment targeting voice (voice group, n = 6), targeting articulation (articulation group, n = 7), or an untreated group (no treatment, n = 6). The severity of dysphonia was assessed by the smoothed cepstral peak prominence (CPPS) and neuronal changes were evaluated by cerebral blood flow (CBF) recorded at baseline, posttreatment, and 7-month follow-up. Only the voice treatment resulted in significant posttreatment improvement in CPPS, which was maintained at 7 months. Following voice treatment, increased activity in left premotor and bilateral auditory cortices was observed at posttreatment, and in the left motor and auditory cortices at 7-month follow-up. Articulation treatment resulted in increased activity in bilateral premotor and left insular cortices that were sustained at a 7-month follow-up. Activation in the auditory cortices and a significant correlation between the CPPS and CBF in motor and auditory cortices was observed only in the voice group. The intensive dosage resulted in long-lasting behavioral and neural effects as the no-treatment group showed a progressive decrease in activity in areas of the speech motor network out to a 7-month follow-up. These results indicate that dysphonia and the speech motor network can be differentially modified by treatment targets, while intensive dosage contributes to long-lasting effects of speech treatments.

Indexed as

DysphoniaParkinson DiseaseHumansSpeechSpeech AcousticsVoice Qualityarticulationdysphoniahypokinetic dysarthriaLSVT LOUDPositron Emission Tomographysmoothed cepstral peak prominencespeech motor network

Identifiers

PMID35141971
PMCPMC8996348
OpenAlexW4211128107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.